Business Wire

Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)

Jaa

Biogen (NASDAQ: BIIB) will present data from its Alzheimer’s disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017.

The planned poster presentations include:

  • Change from Baseline in Clinical Dementia Rating Scale Cognitive and Functional Domains in PRIME, a Randomized Phase 1b Study of the Anti-Amyloid Beta Monoclonal Antibody Aducanumab (BIIB037). Poster 1-053: July 16, 2017, 9:30 a.m. GMT+1. This new post-hoc analysis shows the change in the cognitive and functional subscores, which are derived from the previously reported clinical dementia rating (CDR) score for the overall and early Alzheimer’s disease populations in the 1, 3, 6 and 10 mg/kg aducanumab fixed-dosing cohorts in Phase 1b.

    This poster will be available concurrently with the session on the Investors section of the Biogen company website, www.Biogen.com.
  • Signs and Symptoms of Alzheimer’s Disease Noted in Health Records up to 5 Years Prior to Diagnosis . Poster 2-275: July 17, 2017, 9:30 a.m. GMT+1. This analysis reports the documentation of cognitive and behavioral impairment from U.S. medical health records, prior to an Alzheimer’s disease diagnosis.

About Aducanumab

Aducanumab (BIIB037) is an investigational compound being developed for the treatment of early Alzheimer’s disease. Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment or cognitively impaired elderly subjects with unusually slow cognitive decline using Neurimmune’s technology platform called Reverse Translational Medicine (RTM). Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement.

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook and YouTube.

Biogen Safe Harbor

This press release contains forward-looking statements, including statements relating to the development and potential benefits, safety and efficacy of investigational drugs, including aducanumab and results of certain clinical studies. These statements may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations. You should not place undue reliance on these statements or the scientific data presented. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Factors which could cause actual results to differ materially from our current expectations include the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected, unexpected concerns may arise from additional data or analysis, including data, analysis or results obtained during our clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates, or we may encounter other unexpected hurdles which may be impacted by, among other things, the occurrence of adverse safety events, failure to obtain regulatory approvals in certain jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, third party collaboration risks, and the other risks and uncertainties that are described in the Risk Factors section of Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

Contact information

Biogen
MEDIA CONTACT:
Catherine Falcetti, +1 781-464-3260
public.affairs@biogen.com
or
INVESTOR CONTACT:
Matt Calistri, +1 781-464-2442
IR@biogen.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

OCP Announces Date of 2017 Third Quarter and Nine Month Results22.11.2017 19:59Tiedote

OCP S.A., a global leader in the fertilizer industry, will release its third quarter and nine month 2017 results on Thursday, November 30, 2017. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal at 9 a.m. EDT and 2 p.m. Morocco/London time. OCP senior management will host a conference call to discuss 2017 third quarter/nine month results at 10 a.m. EDT and 3 p.m. Morocco/London time on Thursday, November 30, 2017 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fert

Tata Motors Charts Out 'Connecting Aspirations' As Its New Corporate Brand Identity in Global Markets22.11.2017 17:46Tiedote

As part of the company’s transformation journey undertaken in 2016, Tata Motors commenced a comprehensive project to articulate its corporate branding. Basis a thorough analysis of the existing and the desired future state of the Company, Tata Motors has defined its new brand identity as ‘Connecting Aspirations’ across 46 markets, internationally. ‘Connecting Aspirations’, as the new defining maxim, represents the personality of the brand as an interconnected system of mobility solutions, that are intelligent, perceptive, warm and expressive. It’s a symbolic tagline that represents the company’s past, present and future. It is humble yet bold, a statement as well as a challenge. It will define the way Tata Motors communicates with its internal as well as external stakeholders, and work as an all-encompassing guiding principle across business units.” Speaking on the

NelsonHall Positions L&T Technology Services in the Leaders Category for IoT Services22.11.2017 16:50Tiedote

L&T Technology Services Limited (NSE: LTTS), a leading global pure-play engineering services company announced that it has been positioned in the Leaders Category by independent global research firm, NelsonHall in its latest NEAT evaluation for Internet of Things (IoT) services providers. LTTS is the only global pure-play engineering services to be positioned in the leader’s category. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171122005331/en/ L&T Technology Services Capabilities across IoT Services. (Graphic: Business Wire) LTTS has been identified as a leader relative to its peers’ due to its ability to meet future client requirements as well as deliver immediate benefits to IoT Services clients. Dominique Raviart, IT Services Practice Director, NelsonHall said, “L&T Technol

Smithers Viscient Europe Appoints Alasdair Clipston Director of Chemistry.22.11.2017 13:30Tiedote

Smithers Viscient, a global contract research organisation (CRO), announced the appointment of Alasdair Clipston to the role of Director of Chemistry. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171122005035/en/ Smithers Viscient Europe Appoints Alasdair Clipston Director of Chemistry. (Photo: Business Wire) Clipston joins Smithers with 15 years spent within contract research and testing organisations including AstraZeneca and Charles River. “Alasdair brings great knowledge and experience to our operational leadership team, particularly in residue and physical chemistry including five batch analysis.” said Steve Dean, Managing Director, Smithers Viscient Europe. Dean continues, “His skills and passion for science coupled with excellent client relationships and strong business unde

Mundipharma and APR Applied Pharma Research S.A Announce a New Alliance for the Distribution of Nexodyn® AcidOxidizing Solution in Africa and the Levant22.11.2017 13:30Tiedote

Mundipharma International Corporation Limited (Mundipharma) and APR Applied Pharma Research SA (APR) announce that they have signed a licensing, distribution and marketing agreement for Africa and the Levant Region for the innovative active wound cleanser Nexodyn® AcidOxidizing Solution AOS (Nexodyn® AOS), currently marketed in Europe, Turkey and soon available in Middle East countries. Mundipharma will have exclusive rights to the product in more than 35 African markets and countries of the Levant including Nigeria, Kenya, Egypt, Algeria, Lebanon, Jordan, Tunisia and Morocco. The first launches in these markets will begin in the incoming months following the registration and the obtaining of local authorizations for tariffs and refunds. The global advanced wound care market is expected to grow significantly in the next years as a result of the increasing incidence

The .eu Web Awards Shine Again in 2017 with the Announcement of the Winners22.11.2017 12:00Tiedote

Similar to each of the past 3 years during the month of November, the .eu Web Awards gala generates buzz within the .eu community and domain name industry as a whole. The annual .eu Web Awards, launched in 2014, is a competition where .eu and .ею websites have the chance to be nominated for an opportunity to win an awards package that adds credibility and visibility to their online activity. Of the 15 final nominees, a distinguished jury of European stakeholders chooses the best website in each of the Awards’ five categories. The #2017euWA winners were unveiled at the .eu Web Awards gala that took place yesterday evening at the Theatre du Vaudeville in the heart of Brussels, Belgium. The winners and the special commendations represent an eclectic group, and come from all over the European Union, including Bulgaria (Krina.eu), Latvia (Muniocandela.eu & Letthejourneybegin.eu), Sweden

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme